Microbiota Transplant for PAH

This trial explores a new treatment for pulmonary arterial hypertension (PAH), a condition that causes high blood pressure in the lungs. It tests the safety and practicality of microbiota transplant therapy (MTT) delivered in capsules, combined with antibiotics and fiber supplements, against a placebo. Participants will be divided into three groups to determine which combination might benefit PAH. Individuals diagnosed with PAH and on stable treatment may be suitable for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial does not specify if you need to stop your current medications, but you must be on stable treatment for PAH for one month before joining. If you're on immunosuppressants, you cannot participate.

Research has shown that Microbiota Transplant Therapy (MTT) is safe and feasible for people with pulmonary arterial hypertension (PAH). Studies have found that MTT, which uses healthy bacteria from a donor's gut, does not cause serious side effects. Specifically, patients demonstrated improvements in the six-minute walk test, indicating they tolerated the treatment well. MTT has also been safely used for other conditions, such as Clostridioides difficile colitis, and in individuals with weakened immune systems. These findings support the safety of MTT for treating PAH.¹²³⁴⁵

Most treatments for pulmonary arterial hypertension (PAH) focus on dilating blood vessels or reducing blood pressure. However, the Microbiota Transplant Therapy (MTT) takes a different approach by targeting the gut microbiome. By using microbiota transplants, researchers hope to modify gut bacteria to improve overall health and potentially affect the cardiovascular system. This innovative method is exciting because it explores an entirely new pathway for managing PAH, moving beyond conventional drug treatments like endothelin receptor antagonists or phosphodiesterase inhibitors.

Research has shown that Microbiota Transplant Therapy (MTT) might be a promising treatment for pulmonary arterial hypertension (PAH). In this trial, participants in the Drug Group will receive MTT with antibiotic preconditioning and fiber supplementation. Studies have found that even though only a small amount of donor bacteria remain in patients, MTT can still lower inflammation, which is believed to contribute to PAH. This decrease in inflammation, even if temporary, is encouraging. Previous research confirms that MTT is safe and feasible for people with PAH. These findings suggest that MTT might help manage PAH symptoms by influencing the gut microbiome, the community of tiny organisms living in the intestines.¹²³⁴⁵